PMID- 32739011
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 2162-5514 (Electronic)
IS  - 0074-7742 (Linking)
VI  - 154
DP  - 2020
TI  - The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and 
      neurodegenerative diseases.
PG  - 345-391
LID - S0074-7742(20)30054-4 [pii]
LID - 10.1016/bs.irn.2020.03.023 [doi]
AB  - Evidence increasingly suggests that type 2 diabetes mellitus (T2DM) is a risk 
      factor for neurodegenerative diseases (NDDs), such as Alzheimer's disease (AD) 
      and Parkinson's disease (PD). These diseases share many pathological processes, 
      including oxidative stress, local inflammation/neuroinflammation and chronic, 
      low-grade (systemic) inflammation, which are exacerbated by aging, a common risk 
      factor for T2DM and NDDs. Here, we focus on the link between chronic inflammation 
      driven by peripheral metabolic disease and how this may impact neurodegeneration 
      in AD and PD. We review the relationship between these common pathological 
      processes in AD and PD from the perspective of the "pro-inflammatory" signaling 
      of the nucleotide-binding oligomerization domain (NOD)-, leucine-rich repeat- 
      (LRR)-, and pyrin domain-containing protein 3 (NLRP3) inflammasome complex. Since 
      the need for effective disease-modifying therapies in T2DM, AD and PD is 
      significant, the relationship between these diseases is important as a positive 
      clinical impact on one may benefit the others. We briefly consider how novel 
      strategies may target neuro-inflammation and provide potential therapies for AD 
      and PD.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Soderbom, Grazyna
AU  - Soderbom G
AD  - Klipspringer AB, Savedalen, Sweden. Electronic address: grazyna@klipspringer.se.
FAU - Zeng, Bai-Yun
AU  - Zeng BY
AD  - Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's 
      College London, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200717
PL  - United States
TA  - Int Rev Neurobiol
JT  - International review of neurobiology
JID - 0374740
RN  - 0 (IL18 protein, human)
RN  - 0 (IL1B protein, human)
RN  - 0 (Inflammasomes)
RN  - 0 (Interleukin-18)
RN  - 0 (Interleukin-1beta)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLRP3 protein, human)
SB  - IM
MH  - *Alzheimer Disease/immunology/metabolism/pathology
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/immunology/metabolism
MH  - Humans
MH  - *Inflammasomes/immunology/metabolism
MH  - *Inflammation/immunology/metabolism
MH  - *Interleukin-18/immunology/metabolism
MH  - *Interleukin-1beta/immunology/metabolism
MH  - *NLR Family, Pyrin Domain-Containing 3 Protein/immunology/metabolism
MH  - *Parkinson Disease/immunology/metabolism/pathology
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Chronic inflammation
OT  - Interleukin-18
OT  - Interleukin-1beta
OT  - NLRP3 inflammasome
OT  - Neuroinflammation
OT  - Parkinson's disease
OT  - Type 2 diabetes mellitus
EDAT- 2020/08/03 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/08/03 06:00
PHST- 2020/08/03 06:00 [entrez]
PHST- 2020/08/03 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
AID - S0074-7742(20)30054-4 [pii]
AID - 10.1016/bs.irn.2020.03.023 [doi]
PST - ppublish
SO  - Int Rev Neurobiol. 2020;154:345-391. doi: 10.1016/bs.irn.2020.03.023. Epub 2020 
      Jul 17.